Selskab ramt af forvirring: Nyt navn skal åbne investorernes lommer

Selvom det danske life science-selskab Medtrace allerede har fået tilsagn om investeringer for 100 mio. kr., så er virksomheden endnu ikke i mål med finansieringen af et kommende fase 3-studie. Nu skifter virksomheden navn for at opklare misforståelser blandt potentielle investorer.
Photo: PR, Medtrace
Photo: PR, Medtrace

Den tre år gamle virksomhed Medtrace har tilføjet et 'Pharma' til dets navn for at opklare misforståelser omkring selskabets profil

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading